抗血管内皮生长因子单克隆抗体在非小细胞肺癌中的作用
摘要
非小细胞肺癌(NSCLC)占肺癌的75%,而且它尤为难治,手术是唯一的治疗方法,但是仅有30%的病人在确诊后可以做切除术,而且50%的病人5年内会发生转移。尽管有新的化学治疗,包括基于铂类药物的化疗方法用于不能手术的晚期NSCLC病人,但他们的预后仍然很差.近期东部联合肿瘤学小组的临床实验,以顺氯铂铵+帕特西尼为标准治疗,其他三种基于铂的治疗与之对比,在1155例病人中,总反应率为19%,平均生存时间仅为8.0个月,1年生存率为33%,2年生存率为11%.在几种治疗方法之间,这些参数没有明显差别.类似的结果也见于其它对比研究的报道,包括卡铂加紫杉醇与长春瑞宾加顺铂的疗效对比研究.这些数据反应了现阶段所能做的最好治疗,因此,对于NSCLC迫切需要一种新的治疗方法.
出处
《承德医学院学报》
2006年第3期315-317,共3页
Journal of Chengde Medical University
参考文献16
-
1Schiller JH, Harrington D, Belani CP, et al. Comparison of fourchemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002,346: 92-98.
-
2Folkman J. What is the evidence that tumors are anglogenesis dependent? [J].J Natl Cancer Inst (Bethesda) ,1990,82:4.
-
3Rosen IS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor(VEGF) blockers[J].Cancer Control ,2002, 9(Suppl 2):36.
-
4Galligioni E, Ferro A. Angiogenesis and antiangiogenic agents in non-small cell lung cancer [J]. Lung Cancer,2001,34 (Suppl 4) : S3.
-
5Yuan A, Yu C J, Kuo SH, et al. Vascular endothelial growth factor189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-celllung cancer [J]. J Clin Oncol , 2001, 19:432.
-
6Ushijima C, Tsukamoto S, Yamazaki K, et al. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression[J]. Lung Cancer , 2001,34 : 233.
-
7Koukourakis MI, Giatromanolaki A, Thorpe PE, et al.Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer[J]. Cancer Res, 2000,60:3088-3095.
-
8Passalidou E, TriveUa M, Singh N, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas[J]. Br J Cancer , 2002,86: 244.
-
9Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizurnab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC) : results of a Phase Ⅲ trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracihleucovorin) as first-line therapy in subjects with metastatic CRC [abstract][J]. Proc Am Soc Clin Oncol, 2003,22:3646.
-
10Kabbinavar FF, Wong JT, Ayala RE, et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice[J]. Proc Am Cancer Res ,1995,36:488.
-
1Thlele,J,阮幼冰.慢性髓性白血病的组织学和血液学检查对科隆和弗来堡大学病理研究所604例髂[J].德国医学,2000,17(6):359-363.
-
2第七届全国肿瘤放疗与综合治疗会议暨第二届东部肿瘤放疗协作组学术会议结束[J].中华放射肿瘤学杂志,2011,20(4):300-300.
-
3小细胞肺癌与两种基因突变相关[J].中国肿瘤临床与康复,2015,22(11):1386-1386.
-
4张午临,刘晖,张云杰,苗毅.解毒抗癌方维持治疗中晚期化疗后非小细胞肺癌患者的疗效[J].现代中西医结合杂志,2016,25(3):288-290. 被引量:10
-
5刘桂梅,孙昆良,夏广荣.212例局限期小细胞肺癌放射及综合治疗效果[J].中华放射医学与防护杂志,2008,28(4):381-385. 被引量:6
-
6刘桂梅,孙昆良,夏广荣.212例局限期小细胞肺癌放射及综合治疗效果[J].结核病与胸部肿瘤,2008,0(4):275-279.
-
7白永瑞,傅小龙.第五届东部肿瘤放射治疗协作组(EROG)会议暨“第二届胸部肿瘤放疗及综合治疗进展研讨会”顺利结束[J].中华放射肿瘤学杂志,2016,25(9):988-988.
-
8第七届全国肿瘤放疗及综合治疗会议暨东部肿瘤放疗协助组第二次学术会议征文通知[J].中华放射肿瘤学杂志,2011,20(2):100-100.
-
9李崎,吴伟主.曲妥珠单抗联合多西他赛化疗对Ⅲ期乳腺癌患者的治疗效果及安全性的影响[J].中国生化药物杂志,2017,37(4):34-36. 被引量:2
-
10邵彬,余靖,邸立军,宋国红,朱步东,车利,贾军,姜晗昉,祝毓琳,梁旭,张洁,王超颖,严颖,吕敏,林晓琳,黄晓蕾,尤渺宁,王小利,周心娜,任军.乳腺癌恶性胸腔积液的临床特征及预后因素分析[J].肿瘤防治研究,2013,40(4):381-387. 被引量:11